Brief: Abbisko Cayman Says Oral Pd-L1 Inhibitor Received Clinical Trial Approval From Nmpa Of People's Republic Of China
01/04/2022 03:15
April 1 (Reuters) - Abbisko Cayman Ltd 2256.HK :
* ORAL PD-L1 INHIBITOR RECEIVED CLINICAL TRIAL APPROVAL FROM
NMPA
OF PEOPLE'S REPUBLIC OF CHINA
Source text for Eikon: ID:
Further company coverage: 2256.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Abbisko Cayman
See all newsHK-listed Abbisko climbs most in 12 weeks on Eli Lilly tie-up
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly (updated)
Brief: Abbisko Therapeutics Deepens R+D- Collaboration With Lilly
Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly
Brief: Abbisko Therapeutics Enters Strategic Research Collaboration And License Agreement With Eli Lilly